Product Description: Avotaciclib (BEY1107) is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib can be used in the research of cancer such as pancreatic cancer and lung cancer[1][2].
Applications: Cancer-Kinase/protease
Formula: C13H11N7O
References: [1]Seufferlein T, et, al. Phase I Trials in Pancreatic Cancer. Translational Pancreatic Cancer Research pp 219-232. /[2]Zhang L, et al. Suppression of cyclin-dependent kinase 1 synergizes with checkpoint kinase 2 inhibitor to promote death of non-small cell lung cancer cells with radiotherapeutic resistance. Journal of Radiation Research and Applied Sciences, 2024, 17(2): 100900.
CAS Number: 1983983-41-0
Molecular Weight: 281.27
Compound Purity: 99.72
Research Area: Cancer
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Apoptosis;CDK
Deutsch
English
